MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy
MCC950-beladene M12-Liposom-Nanopartikel zur gezielten Hemmung des NLRP3-Inflammasoms bei sepsisinduzierter Muskelatrophie
Journal of Cachexia, Sarcopenia and Muscle · 2026-04 · 17 (2)
DOI: 10.1002/jcsm.70285 ↗Auf einen Blick
In Zell- und Mausmodellen der sepsisinduzierten Myopathie hemmten M12-Liposome@MCC950 NPs das NLRP3-Inflammasom und verminderten Muskelatrophie. Die Nanopartikel zeigten zudem keine Leber- oder Nierentoxizität.
Fragestellung
Verbessert eine muskelgerichtete, MCC950-beladene Liposom-Nanopartikel-Formulierung die Hemmung des NLRP3-Inflammasoms bei sepsisinduzierter Muskelatrophie?
Methode
Nanopartikel mit M12-Oberflächenmodifikation; Charakterisierung per TEM, DLS und Freisetzungsassay. Targeting in vivo per Fluoreszenzbildgebung, in vitro in C2C12-Myoblasten. Prüfung in LPS- und CLP-Modellen sowie Sicherheitsanalyse.
Ergebnisse
Die Partikel hatten eine mittlere Größe von 150 ± 10 nm und eine Zeta-Potential von −15,73 ± 6,03 mV. In vivo stieg die Anreicherung im Muskel um das 3,47- bis 5,31-Fache; die zelluläre Aufnahme um das 2,28-Fache.
Schlussfolgerung der Autor:innen
M12-Liposome@MCC950 NPs liefern MCC950 gezielt und mit verzögerter Freisetzung an Skelettmuskel, hemmen das NLRP3-Inflammasom und lindern SIM bei geringerer systemischer Toxizität.
Kernaussagen
- Sustained release über 14 Tage
- Mehr Muskelanreicherung und höhere Zellaufnahme als nicht zielgerichtete Kontrollen
- Keine hepatische oder renale Toxizität in den Analysen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 15.04.2026. Verfasst von Yukun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Aesthetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Sepsis, Nanoparticles, NLR Family, Pyrin Domain-Containing 3 Protein, Furans. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Provincial Natural Science Foundation of China, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis‐induced myopathy (SIM) is a severe complication that contributes to late‐stage mortality and functional impairment in sepsis patients. The NLRP3 inflammasome plays a pivotal role in the pathogenesis of SIM, and its selective inhibitor MCC950 has shown promising therapeutic potential. However, systemic administration of MCC950 is limited by hepatotoxicity, necessitating the development of targeted delivery systems to enhance efficacy while minimizing toxicity.
Methods
To improve the therapeutic profile of MCC950, we designed M12‐functionalized liposomal nanoparticles (M12‐Liposome@MCC950 NPs) as the carrier material, with surface modification by the muscle‐homing peptide M12 for targeted delivery to skeletal muscle tissue. Nanoparticle characteristics were assessed using transmission electron microscopy (TEM), dynamic light scattering (DLS) and in vitro drug release assays. The targeting efficiency was evaluated in vivo using fluorescence imaging and in vitro via cellular uptake studies in C2C12 myoblasts. The anti‐inflammatory and anti‐atrophic effects were investigated in an LPS‐induced myotube atrophy model and a cecal ligation and puncture (CLP)‐induced sepsis mouse model. Biocompatibility and systemic safety were assessed through histological analysis and serum biochemical assays.
Results
M12‐Liposome@MCC950 NPs exhibited a uniform spherical morphology, an average diameter of 150 ± 10 nm and a zeta potential of −15.73 ± 6.03 mV, ensuring good colloidal stability. The nanoparticles demonstrated sustained drug release over 14 days. In vivo fluorescence imaging confirmed enhanced skeletal muscle accumulation of M12‐conjugated nanoparticles, with a 3.47‐ to 5.31‐fold increase compared to nontargeted controls. Cellular uptake studies revealed a 2.28‐fold improvement in intracellular delivery efficiency. In vitro, M12‐Liposome@MCC950 NPs significantly inhibited NLRP3 inflammasome activation, reducing caspase‐1 cleavage and IL‐1β/IL‐18 secretion, while also preventing LPS‐induced myotube atrophy. In the CLP‐induced sepsis model, treatment with M12‐Liposome@MCC950 NPs markedly reduced muscle atrophy, improved grip strength and decreased expression of atrophy‐related proteins Atrogin‐1 and MuRF1. Additionally, histological and biochemical assessments confirmed that the nanoparticles did not induce hepatic or renal toxicity, demonstrating excellent biocompatibility.
Conclusions
M12‐Liposome@MCC950 NPs provide a targeted and sustained‐release strategy for delivering MCC950 to skeletal muscle, effectively inhibiting NLRP3 inflammasome activation and alleviating SIM. This approach enhances therapeutic efficacy while mitigating systemic toxicity, highlighting the potential of nanomedicine‐based interventions for treating inflammation‐related myopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Aesthetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Division of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Sino-German Research Institute of Disaster Medicine, Wuhan, China.
- Department of Orthopedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Yuchang Wang
Förderung
- National Natural Science Foundation of China
- Hubei Provincial Natural Science Foundation of China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Tongji Hospital
Zitieren
APA
Liu, Y., Wang, K., Xu, Z., Zhao, X., Li, Z., Bai, X., Zhu, H., Gao, F., Zhu, L., & Wang, Y. (2026). MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy. Journal of Cachexia, Sarcopenia and Muscle, 17(2). https://doi.org/10.1002/jcsm.70285
Vancouver
Liu Y, Wang K, Xu Z, Zhao X, Li Z, Bai X, et al. MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2). doi:10.1002/jcsm.70285
BibTeX
@article{Liu2026,
author = {Liu, Yukun and Wang, Kang and Xu, Zhikai and Zhao, Xuan and Li, Zhanfei and Bai, Xiangjun and Zhu, Hao and Gao, Fangli and Zhu, Liang and Wang, Yuchang},
title = {MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {2},
doi = {10.1002/jcsm.70285}
}
EUVIMED